Treatment of experimental hepatic fibrosis by combinational delivery of urokinase-type plasminogen activator and hepatocyte growth factor genes

Liver International

Volumn 25, Issue 4, 2005, Pages 796-807

  Lin, Yong ^a   Xie, Wei Fen ^a   Chen, Yue Xiang ^a   Zhang, Xin ^b   Zeng, Xin ^a   Qiang, Hui ^a   Chen, Wei Zhong ^a   Yang, Xiu Jiang ^a   Han, Ze Guang ^b   Zhang, Zhong Bing ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

Author keywords

Adenovirus; Gene therapy; Hepatic fibrosis; Hepatocyte growth factor (HGF); Urokinase type plasminogen activator (uPA)

Indexed keywords

ADENOVIRUS VECTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 3; GELATINASE A; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UROKINASE;

ANALYSIS OF VARIANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GENETIC TRANSFECTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER CELL; LIVER FIBROSIS; MALE; MONOTHERAPY; NONHUMAN; NORTHERN BLOTTING; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STELLATE CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; FIBRILLAR COLLAGENS; GENE THERAPY; GENETIC VECTORS; HEPATOCYTE GROWTH FACTOR; HEPATOCYTES; HUMANS; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MATRIX METALLOPROTEINASE 2; PROTO-ONCOGENE PROTEINS C-MET; RATS; RATS, SPRAGUE-DAWLEY; TRANSFECTION; URINARY PLASMINOGEN ACTIVATOR;

EID: 22844448409     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01098.x     Document Type: Article

References (37)

1. Friedman S L. The cellular basis of hepatic fibrosis: mechanisms and treatment strategies. N Engl J Med 1993; 328: 1828-35.
2. Friedman S L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-50.
3. Rockey D C. Gene therapy for hepatic fibrosis-bringing treatment into the new millennium. Hepatology 1999; 30: 816-8.
4. Shetty K, Wu G Y, Wu C H. Gene therapy of hepatic diseases: prospects for the new millennium. Gut 2000; 46: 136-9.
5. Beljaars L, Meijer D K, Poelstra K. Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis. Front Biosci 2002; 7: e214-22.
6. Davern T J. Molecular therapeutics of liver disease. Clin Liver Dis 2001; 5: 381-414, vi.
7. Qi Z, Atsuchi N, Ooshima A, et al. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci USA 1999; 96: 2345-9.
8. Chen Y X, Lu C H, Xie W F, et al. Effect of ribozyme against platelet-derived growth factor receptor beta subunit mRNA on the biological characters of hepatic stellate cells. Zhonghua Gan Zang Bing Za Zhi 2003; 11: 278-81.
9. Iimuro Y, Nishio T, Morimoto T, et al. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology 2003; 124: 445-58.
10. Rudolph K L, Chang S, Millard M, et al. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000; 287: 1253-8.
11. Boros P, Miller C M. Hepatocyte growth factor: a multifunctional cytokine. Lancet 1995; 345: 293-5.
12. Ueki T, Kaneda Y, Tsutsui H, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999; 5: 226-30.
13. Xue F, Takahara T, Yata Y, et al. Hepatocyte growth factor gene therapy accelerates regeneration in cirrhotic mouse livers after hepatectomy. Gut 2003; 52: 694-700.
14. Murphy G, Atkinson S, Ward R, et al. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann N Y Acad Sci 1992; 667: 1-12.
15. Salgado S, Garcia J, Vera J, et al. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol Ther 2000; 2: 545-51.
16. He T C, Zhou S, da Costa Lt, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-14.
17. Lieber A, Peeters M J, Gown A, et al. A modified urokinase plasminogen activator induces liver regeneration without bleeding. Hum Gene Ther 1995; 6: 1029-37.
18. Howard R B, Lee J C, Pesch L A. The fine structure, potassium content, and respiratory activity of isolated rat liver parenchymal cells prepared by improved enzymatic techniques. J Cell Biol 1973; 57: 642-58.
19. Seglen P O. Preparation of isolated rat liver cells. Methods Cell Biol 1976; 13: 29-83.
20. Ding X Z, Smallridge R C, Galloway R J, et al. Rapid assay of HSF1 and HSF2 gene expression by RT-PCR. Mol Cell Biochem 1996; 158: 189-92.
21. Netzel-Arnett S, Mitola D J, Yamada S S, et al. Collagen dissolution by keratinocytes requires cell surface plasminogen activation and matrix metalloproteinase activity. J Biol Chem 2002; 277: 45154-61.
22. Jamall I S, Finelli V N, Que Hee S S. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem 1981; 15: 70-5.
23. Perez M J, Suarez A, Gomez-Capilla J A, et al. Dietary nucleotide supplementation reduces thioacetamide-induced liver fibrosis in rats. J Nutr 2002; 132: 652-7.
24. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
25. Alcolado R, Arthur M J, Iredale J P. Pathogenesis of liver fibrosis. Clin Sci 1997; 92: 103-12.
26. Delhaye M, Louis H, Degraef C, et al. Relationship between hepatocyte proliferative activity and liver functional reserve in human cirrhosis. Hepatology 1996; 23: 1003-11.
27. Mizuguchi H, Kay M A. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 1999; 10: 2013-7.
28. Nakatani T, Kuriyama S, Tominaga K, et al. Assessment of efficiency and safety of adenovirus mediated gene transfer into normal and damaged murine livers. Gut 2000; 47: 563-70.
29. Iredale J P, Murphy G, Hembry R M, et al. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. J Clin Invest 1992; 90: 282-7.
30. Leyland H, Gentry J, Arthur M J, et al. The plasminogen-activating system in hepatic stellate cells. Hepatology 1996; 24: 1172-8.
31. Zhang L P, Takahara T, Yata Y, et al. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells. J Hepatol 1999; 31: 703-11.
32. Phaneuf D, Chen S J, Wilson J M. Intravenous injection of an adenovirus encoding hopatocyte growth factor results in liver growth and has a protective effect against apoptosis. Mol Med 2000; 6: 96-103.
33. Matsuno Y, Iwata H, Umeda Y, et al. Hepatocyte growth factor gene transfer into the liver via the portal vein using electroporation attenuates rat liver cirrhosis. Gene Ther 2003; 10: 1559-66.
34. Yasuda H, Imai E, Shiota A, et al. Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats. Hepatology 1996; 24: 636-42.
35. Muruve D A, Barnes M J, Stillman I E, et al. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 1999; 10: 965-76.
36. Prieto J, Herraiz M, Sangro B, et al. The promise of gene therapy in gastrointestinal and liver diseases. Gut 2003; 52(Suppl. 2): ii49-54.
37. Oshikawa K, Shi F, Rakhmilevich A L, et al. Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1beta converting enzyme cdna. Proc Natl Acad Sci USA 1999; 96: 13351-6.